Advances in the early diagnosis of hepatocellular carcinoma

Genes and Diseases

Chao Wei¹  Weiyi Wang² 

[1] Corresponding author. Xiamen Amplly Bio-engineering Co., Ltd, 10 Yangguang Street, Haicang District, Xiamen, PR China.;Xiamen Amplly Bio-engineering Co., Ltd, Xiamen, PR China;

关键词: Biomarker;    Early diagnosis;    Hepatocellular carcinoma;    Imaging;    Liquid biopsy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to the declining death rates observed for all other common cancers such as breast, lung, and prostate cancers, the death rates for HCC continue to increase by ~2–3% per year because HCC is frequently diagnosed late and there is no curative therapy for an advanced HCC. The early diagnosis of HCC is truly a big challenge. Over the past years, the early diagnosis of HCC has relied on surveillance with ultrasonography (US) and serological assessments of alpha-fetoprotein (AFP). However, the specificity and sensitivity of US/AFP is not satisfactory enough to detect early onset HCC. Recent technological advancements offer hope for early HCC diagnosis. Herein, we review the progress made in HCC diagnostics, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.

【 授权许可】

Unknown